🔗 Share this article

As the US proceeds with historic changes to its vaccination schedules, a particular individual appears in a surprising turn: Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on COVID-19 vaccines in the global health crisis and has concentrated on alleged fatalities following COVID-19 immunization in her recent time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Program

Public health authorities planned to reveal major changes to the childhood immunization program in December, aligning the US with the Danish immunization schedule, it is understood – a major change that would put the US at odds with much of the world with little proof for improved outcomes. The planned update has been pushed back until the next year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the gathering. She was recently named interim head of the FDA’s CDER, the fifth person to run the center this year.

A Shift at the Agency

This interim role could signify a closer partnership between the drug and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it points to a greater focus upon rolling back long-standing vaccines at the FDA.

The new acting director has frequently advocated for halting some pediatric vaccine recommendations in the US to become more in line with Denmark, a nation with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on immunizations – traditionally the domain of Dr. Prasad, chief of the FDA’s vaccine center – instead of pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious track record in drug development, approval processes or management, which has been typical for previous heads of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, stated Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in leading a sizeable institution. She lacks background in industry regulation.”

Former directors of the center would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who led the center have had.”

CDER has an vast workload at the agency, Woodcock emphasized.

“The public just zeroes in on the new drug program, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and other areas, and every single one need to be managed,” Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative component to the job, which supervises more than 5,000 employees. “It is a enormous management job, if you perform it correctly,” she concluded.

Response and Disputed Programs

In response to inquiries about Dr. Høeg's credentials and whether this assignment indicates greater collaboration among FDA leaders on immunizations, a representative said that the “inquiries are based on flawed premises”.

“This background is consistent with the functions of her role,” the representative explained, citing the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg takes over the commissioner’s new fast-track approval initiative, a controversial rapid drug-approval program that reportedly worried her predecessors. “How are these therapies being chosen for this expedited pathway? Who takes the decisions?” Howard said. “There is a lot of secrecy occurring at the agency right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards less stringent regulations of most medications, except for immunizations.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if troubling, history, critics observe. She authored a study using non-validated crowd-sourced reports to estimate the rate of heart inflammation after COVID-19 immunization. She advised the state of Florida top health official Joseph Ladapo, who was said to have altered data to indicate Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the new government encompassed altering regulations for novel immunizations and ending “optional” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of barring young men from obtaining Covid vaccinations.

“She is an all-around ideologue who starts off with her preconceived notions and works backwards to retrofit the evidence in a very disingenuous, fraudulent fashion,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg became part of fellow contrarians, {like|